{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T20:57:20Z","timestamp":1763499440789,"version":"3.45.0"},"reference-count":33,"publisher":"CSIRO Publishing","issue":"2","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":3010,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Thiazide diuretics are commonly prescribed in the treatment of hypertension. However, thiazide diuretics may not all be equal in their ability to reduce cardiovascular disease outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIM<\/jats:title>\n                    <jats:p>To determine if bendroflumethiazide\/bendrofluazide, the most commonly used diuretic for hypertension in New Zealand, is as effective as other diuretics in terms of cardiovascular disease outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Using recent reviews of thiazide-like (chlorthalidone or indapamide) and thiazide-type diuretics (hydrochlorothiazide and bendrofluazide) and a separate search of bendrofluazide, data on cardiovascular disease outcomes was extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Nineteen relevant papers with 21 comparisons were found. All thiazide-based diuretics have been reported in at least one trial showing them to be more effective than placebo for cardiovascular disease outcomes, with the exception of chlorothiazide. There were no comparisons of bendrofluazide alone with other medications, but there were two studies with either bendrofluazide or hydrochlorothiazide compared with \u03b2-blockers; however, the pooled relative risk (RR) was not significant (RR = 1.10 (95% CI, 0.84\u20131.43)). For chlorthalidone, there were four comparisons with other medications, and the summary RR was statistically significant for cardiovascular disease outcomes (RR = 0.91 (95% CI, 0.85\u20130.98)). Chlorthalidone was significantly more effective for some cardiovascular disease outcomes when compared with doxazosin, amlodipine and lisinopril.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>All thiazide-based medicines available in New Zealand are effective in terms of cardiovascular disease outcomes compared with placebo when used for treating hypertension, with the exception of chlorothiazide. Of the diuretics available in New Zealand for hypertension, only chlorthalidone has been shown to be more effective than other blood pressure-lowering medicines. It may be time to change from using bendrofluazide and start using chlorthalidone as a treatment for hypertension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/hc16038","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T02:48:03Z","timestamp":1529549283000},"page":"105-113","source":"Crossref","is-referenced-by-count":2,"title":["Should we switch from bendrofluazide to chlorthalidone as the initial treatment for hypertension? A review of the available medication"],"prefix":"10.1071","volume":"9","author":[{"given":"Bruce","family":"Arroll","sequence":"first","affiliation":[{"name":"ADepartment of General Practice and Primary Health Care, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Wallace","sequence":"additional","affiliation":[{"name":"ADepartment of General Practice and Primary Health Care, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"2025111814494517000_R1","first-page":"13","article-title":"Time to talk about prescriptions.","volume":"10","author":"Britten","year":"1999","journal-title":"Prescriber."},{"key":"2025111814494517000_R2","first-page":"14","article-title":"Which antihypertensive?","volume":"31","author":"Best Practice Advocacy Centre New Zealand","year":"2010","journal-title":"Best Practice Journal."},{"issue":"12","key":"2025111814494517000_R3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/ajh\/hpv050","article-title":"Cardioprotective effect of thiazide-like diuretics: a meta-analysis.","volume":"28","author":"Chen","year":"2015","journal-title":"Am J Hypertens."},{"key":"2025111814494517000_R4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","article-title":"Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality systematic review and meta-analysis.","volume":"65","author":"Olde Engberink","year":"2015","journal-title":"Hypertension."},{"issue":"5","key":"2025111814494517000_R5","first-page":"CD003824","article-title":"Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.","volume":"29","author":"Musini","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"issue":"10","key":"2025111814494517000_R6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.amjmed.2011.05.009","article-title":"Half a century of hydrochlorothiazide: facts, fads, fiction, and follies.","volume":"124","author":"Messerli","year":"2011","journal-title":"Am J Med."},{"key":"2025111814494517000_R7"},{"issue":"4","key":"2025111814494517000_R8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1474-4422(09)70025-0","article-title":"Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review.","volume":"8","author":"Feigin","year":"2009","journal-title":"Lancet Neurol."},{"issue":"13","key":"2025111814494517000_R9","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1001\/jama.1988.03720130040027","article-title":"Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.","volume":"259","author":"Wikstrand","year":"1988","journal-title":"JAMA."},{"issue":"6488","key":"2025111814494517000_R10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","article-title":"MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.","volume":"291","author":"MRC Working Party","year":"1985","journal-title":"Br Med J (Clin Res Ed)."},{"issue":"5","key":"2025111814494517000_R11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00004872-198710000-00009","article-title":"Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.","volume":"5","author":"Wilhelmsen","year":"1987","journal-title":"J Hypertens."},{"issue":"8181","key":"2025111814494517000_R12","first-page":"1261","article-title":"The Australian therapeutic trial in mild hypertension. Report by the Management Committee.","volume":"1","author":"Reader","year":"1980","journal-title":"Lancet."},{"issue":"5, Suppl 1","key":"2025111814494517000_R13","first-page":"I98","article-title":"Treatment of mild hypertension: results of a ten-year intervention trial.","volume":"40","author":"Smith","year":"1977","journal-title":"Circ Res."},{"issue":"23","key":"2025111814494517000_R14","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).","volume":"288","author":"Furberg","year":"2002","journal-title":"JAMA."},{"issue":"15","key":"2025111814494517000_R15","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT).","volume":"283","author":"Furberg","year":"2000","journal-title":"JAMA."},{"issue":"1","key":"2025111814494517000_R16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/01.STR.20.1.4","article-title":"Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.","volume":"20","author":"Perry","year":"1989","journal-title":"Stroke."},{"issue":"24","key":"2025111814494517000_R17","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.","volume":"265","author":"Ernst","year":"1991","journal-title":"JAMA."},{"issue":"3","key":"2025111814494517000_R18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1080\/08037050310009545","article-title":"Treatment of isolated systolic hypertension: the SHELL study results.","volume":"12","author":"Malacco","year":"2003","journal-title":"Blood Press."},{"issue":"8442","key":"2025111814494517000_R19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(85)91783-0","article-title":"Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.","volume":"325","author":"Amery","year":"1985","journal-title":"Lancet."},{"issue":"10","key":"2025111814494517000_R20","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.1996.03540100029024","article-title":"Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial.","volume":"276","author":"Borhani","year":"1996","journal-title":"JAMA."},{"issue":"9227","key":"2025111814494517000_R21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet."},{"issue":"23","key":"2025111814494517000_R22","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med."},{"issue":"6824","key":"2025111814494517000_R23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.","volume":"304","author":"Party","year":"1992","journal-title":"BMJ."},{"issue":"11","key":"2025111814494517000_R24","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jama.1967.03130240070013","article-title":"Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg.","volume":"202","author":"Veterans Administration Cooperative Study Group","year":"1967","journal-title":"JAMA."},{"key":"2025111814494517000_R25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jama.1970.03170330025003","article-title":"Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg.","volume":"213","author":"Veterans Administration Cooperative Study Group","year":"1970","journal-title":"JAMA."},{"issue":"7","key":"2025111814494517000_R26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly.","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med."},{"issue":"18","key":"2025111814494517000_R27","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older.","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med."},{"issue":"12","key":"2025111814494517000_R28","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1097\/00004872-200312000-00030","article-title":"Results of the pilot study for the Hypertension in the Very Elderly Trial.","volume":"21","author":"Bulpitt","year":"2003","journal-title":"J Hypertens."},{"issue":"5","key":"2025111814494517000_R29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/0002-9343(80)90438-6","article-title":"Treatment of mild hypertension: a five year controlled drug trial. The Oslo study.","volume":"69","author":"Helgeland","year":"1980","journal-title":"Am J Med."},{"issue":"4","key":"2025111814494517000_R30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bcp.12499","article-title":"A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?","volume":"79","author":"Barber","year":"2015","journal-title":"Br J Clin Pharmacol."},{"issue":"11","key":"2025111814494517000_R31","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1097\/00004872-199816110-00014","article-title":"The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness.","volume":"16","author":"Zanchetti","year":"1998","journal-title":"J Hypertens."},{"issue":"6","key":"2025111814494517000_R32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/HYPERTENSIONAHA.112.191106","article-title":"Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses.","volume":"59","author":"Roush","year":"2012","journal-title":"Hypertension."},{"issue":"2","key":"2025111814494517000_R33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00004872-200302000-00003","article-title":"The ALLHAT trial: strengths and limitations.","volume":"21","author":"Fagard","year":"2003","journal-title":"J Hypertens."}],"container-title":["The Journal of Primary Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/9\/2\/105\/1326960\/hc16038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/9\/2\/105\/1326960\/hc16038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T19:49:55Z","timestamp":1763495395000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/hc\/article\/9\/2\/105\/194453\/Should-we-switch-from-bendrofluazide-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,9]]},"published-print":{"date-parts":[[2017,6,30]]}},"URL":"https:\/\/doi.org\/10.1071\/hc16038","relation":{},"ISSN":["1172-6156"],"issn-type":[{"type":"electronic","value":"1172-6156"}],"subject":[],"published":{"date-parts":[[2017,6,9]]}}}